Histopathologi̇c evaluation of ototoxi̇c si̇de effects of topically applied antifungal drugs
Is this your thesis?
This record came from a bulk archive import. If it’s yours, link it to your profile.
Abstract (EN)
There is a lack of data regarding ototoxicity of topically applied antimycotics. In this study, the ototoxicity of tolnaftat, sulcanosole, bifonasole and nystatin was studied in 35 guinea pigs. Neomisin was applied as a positive control group. Drugs was injected into the right tympanic cavity, three times in a week. Left ears were evaluated as a negative control group. Animals were sacrified two weeks after treatment and the cochleas were examined under light microscopy and electron microscopy. The percentage of apoptotic cells in spiral limbus and spiral ganglion were determined by TUNEL method. The percentage of apoptotic cells were higher in ears which tolnaftat and bifonasole were applied, than in ears which sulconasole and nystatin were applied. This findings indicated that antimycotics might cause ototoxicity by apoptosis, this effect can be seen not only in organ of Corti but also in spiral limbus and spiral ganglion.
Author
Gülay Güçlü
Institution
How to Cite
Gülay Güçlü (Medical Specialty Thesis). Histopathologi̇c evaluation of ototoxi̇c si̇de effects of topically applied antifungal drugs, 2005, Manisa Celal Bayar University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Manisa Celal Bayar University
- Investigation of the relationship of internet addiction level of high school students with parents' attitudes: The case of Manisa(2019)
- Aşık Kamandar Efendiyev life, art and works(2004)
- Analysing the social integration process of yezidi refugee youngs in the context of multiculturalist social work(2016)
- The security matter of Turkey?s Islands? sea (Eagean sea)(2007)
- Sağlıklı genç erkek ve kadın bireylerde solunum fonksiyon testlerinin analizi(2021)
- Middle income trap problem in terms of sustainable growth resources in Turkiye(2023)
